An Open-Label, Multicentre, Dose-Escalation Phase IB Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonist) in Combination With Atezolizumab (Anti PD-L1) in Patients With Locally Advanced and/or Metastatic Solid Tumours
This is an open-label, multicentre study designed to assess the safety, pharmacokinetics,
pharmacodynamics and activity of RO7009789 administered in combination with atezolizumab
(ATZ) in participants with metastatic or locally advanced solid tumours. The study will be
conducted in three Parts (I, II, and III), with part I divided into Parts IA and IB. All
participants will be followed up for survival until death or loss of follow-up after the
last visit or withdrawal of consent.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society